Skip to main content
Top
Published in: Rheumatology International 9/2022

21-03-2022 | Psoriatic Arthritis | Observational Research

Assessment of autonomic dysfunction with the COMPASS-31 and its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis

Authors: Halise Hande Gezer, Didem Erdem Gürsoy, Sevtap Acer Kasman, Mehmet Tuncay Duruöz

Published in: Rheumatology International | Issue 9/2022

Login to get access

Abstract

This study aimed to evaluate the autonomic dysfunction as assessed by the Composite Autonomic Symptom Score-31 (COMPASS-31) as well as its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis (PsA). This cross-sectional observational study involved 118 PsA patients (85 females, mean age 45.6 years) and 64 healthy subjects. Cardiovascular risks were recorded including body mass index (BMI), hypertension (HT), diabetes mellitus (DM), dyslipidemia, metabolic syndrome (MetS), and 10-year Framingham Risk scores (FRS) were calculated. PsA was assessed with regard to disease activity, quality of life, and function. Autonomic dysfunction was evaluated using the COMPASS-31 consisting of six subdivisions including orthostatic, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor functions. The mean disease duration was 63.3 months. The mean total COMPASS-31 score was significantly higher in PsA patients than in controls (24.4 vs 11.1; p < 0.001), as were all sub-domain scores. COMPASS-31 scores were significantly lower in patients with DAPSA-REM and MDA. The COMPASS-31 total score showed significant correlations with scores of pain, global assessment, fatigue, function, quality of life, DAPSA, and BASDAI (p < 0.05).The presence of HT, dyslipidemia, MetS, and abdominal obesity did not significantly affect the total COMPASS-31 and sub-domain scores, except for the secretomotor scores being significantly higher in patients with abdominal obesity and MetS (p < 0.05). COMPASS-31 scores were not significantly different across the FRS risk groups. The symptoms of autonomic dysfunction are prevalent in PsA patients. High disease activity and pain have negative effects on autonomic function, and also functional impairment, fatigue, and poor quality of life are associated with autonomic dysfunction. However, the COMPASS-31 was found to be insufficient to demonstrate a clear relationship between autonomic dysfunction and cardiovascular risk.
Literature
10.
go back to reference Moog P, Valda K, Eren OE, Rauschel V, Kossegg SJ, Bachmann Q, Schmaderer C, Straube A, Schulze-Koops H, Witt M (2019) A complex pattern of autonomic dysfunction in familial Mediterranean fever. Results from a controlled cross-sectional study. Clin Exp Rheumatol 37(Suppl 121):35–42PubMed Moog P, Valda K, Eren OE, Rauschel V, Kossegg SJ, Bachmann Q, Schmaderer C, Straube A, Schulze-Koops H, Witt M (2019) A complex pattern of autonomic dysfunction in familial Mediterranean fever. Results from a controlled cross-sectional study. Clin Exp Rheumatol 37(Suppl 121):35–42PubMed
13.
18.
go back to reference Tälli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Cañete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, Kalyoncu U, Kiltz U, Maccarone M, Niedermayer D, Otsa K, Scrivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L (2016) Patient global assessment in psoriatic arthritis—what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Jt Bone Spine 83:335–340. https://doi.org/10.1016/j.jbspin.2015.06.018CrossRef Tälli S, Etcheto A, Fautrel B, Balanescu A, Braun J, Cañete JD, de Vlam K, de Wit M, Heiberg T, Helliwell P, Kalyoncu U, Kiltz U, Maccarone M, Niedermayer D, Otsa K, Scrivo R, Smolen JS, Stamm T, Veale DJ, Kvien TK, Gossec L (2016) Patient global assessment in psoriatic arthritis—what does it mean? An analysis of 223 patients from the Psoriatic arthritis impact of disease (PsAID) study. Jt Bone Spine 83:335–340. https://​doi.​org/​10.​1016/​j.​jbspin.​2015.​06.​018CrossRef
20.
23.
go back to reference (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 68:899–917. https://doi.org/10.1093/ajcn/68.4.899 (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 68:899–917. https://​doi.​org/​10.​1093/​ajcn/​68.​4.​899
31.
go back to reference Campbell MJ, Swinscow TDV (2009) Statistics at square one. Wiley-Blackwell, West Sussex Campbell MJ, Swinscow TDV (2009) Statistics at square one. Wiley-Blackwell, West Sussex
Metadata
Title
Assessment of autonomic dysfunction with the COMPASS-31 and its relationship with disease activity and cardiovascular risks in patients with psoriatic arthritis
Authors
Halise Hande Gezer
Didem Erdem Gürsoy
Sevtap Acer Kasman
Mehmet Tuncay Duruöz
Publication date
21-03-2022
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2022
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-022-05110-7

Other articles of this Issue 9/2022

Rheumatology International 9/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare